BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38105215)

  • 21. RecQ mediated genome instability 2 (
    Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
    Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive multi-omics analysis of the m7G in pan-cancer from the perspective of predictive, preventive, and personalized medicine.
    Huang X; Chen Z; Xiang X; Liu Y; Long X; Li K; Qin M; Long C; Mo X; Tang W; Liu J
    EPMA J; 2022 Dec; 13(4):671-697. PubMed ID: 36505892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pan-cancer Multi-omics Analysis Reveals HMGN1 as a Potential Prognostic and Immune Infiltration-associated Biomarker.
    Guo Y; Zhang R; Xu H; Hong K; Cen K; Mai Y; Wu Z
    Curr Med Chem; 2024 Jan; ():. PubMed ID: 38310387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and interpretation of a pathomics-based model for the prediction of microsatellite instability in Colorectal Cancer.
    Cao R; Yang F; Ma SC; Liu L; Zhao Y; Li Y; Wu DH; Wang T; Lu WJ; Cai WJ; Zhu HB; Guo XJ; Lu YW; Kuang JJ; Huan WJ; Tang WM; Huang K; Huang J; Yao J; Dong ZY
    Theranostics; 2020; 10(24):11080-11091. PubMed ID: 33042271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy.
    Bao X; Zhang H; Wu W; Cheng S; Dai X; Zhu X; Fu Q; Tong Z; Liu L; Zheng Y; Zhao P; Fang W; Liu F
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
    Zhao Q; Gao S; Chen X; Zhu X
    Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pan-cancer analysis of SYNGR2 with a focus on clinical implications and immune landscape in liver hepatocellular carcinoma.
    Liu C; Qu Z; Zhao H; Wang P; Zhan C; Zhang Y
    BMC Bioinformatics; 2023 May; 24(1):192. PubMed ID: 37170221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transomics2cytoscape: an automated software for interpretable 2.5-dimensional visualization of trans-omic networks.
    Nishida K; Maruyama J; Kaizu K; Takahashi K; Yugi K
    NPJ Syst Biol Appl; 2024 Feb; 10(1):16. PubMed ID: 38374087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survey and comparative assessments of computational multi-omics integrative methods with multiple regulatory networks identifying distinct tumor compositions across pan-cancer data sets.
    Wei Z; Zhang Y; Weng W; Chen J; Cai H
    Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32533167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAS-viewer: web-based tool for splicing-guided integrative analysis of multi-omics cancer data.
    Han S; Kim D; Kim Y; Choi K; Miller JE; Kim D; Lee Y
    BMC Med Genomics; 2018 Apr; 11(Suppl 2):25. PubMed ID: 29697367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multi-omics and single-cell sequencing analyses reveal the potential significance of circadian pathways in cancer therapy.
    Lai H; Xiang X; Long X; Chen Z; Liu Y; Huang X
    Expert Rev Mol Diagn; 2024; 24(1-2):107-121. PubMed ID: 38288973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the role of Frizzled 2 in different cancer types.
    Zhou M; Sun X; Zhu Y
    FEBS Open Bio; 2021 Apr; 11(4):1195-1208. PubMed ID: 33565732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
    Wang Y; Gong H; Cao Y
    Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pan-cancer identification of clinically relevant genomic subtypes using outcome-weighted integrative clustering.
    Arora A; Olshen AB; Seshan VE; Shen R
    Genome Med; 2020 Dec; 12(1):110. PubMed ID: 33272320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AVBAE-MODFR: A novel deep learning framework of embedding and feature selection on multi-omics data for pan-cancer classification.
    Li M; Guo H; Wang K; Kang C; Yin Y; Zhang H
    Comput Biol Med; 2024 Jul; 177():108614. PubMed ID: 38796884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Pan-Cancer Multi-Omics Landscape of FOXO Family Relevant to Clinical Outcome and Drug Resistance.
    Xie J; Zhang J; Tian W; Zou Y; Tang Y; Zheng S; Wong CW; Deng X; Wu S; Chen J; Mo Y; Xie X
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma.
    Zhang Z; Zhang X; Huang A
    Front Oncol; 2021; 11():718589. PubMed ID: 34485153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SHCBP1 Is a Prognostic Biomarker Related to the Tumour Immune Microenvironment in Pan-Cancer.
    Huang Y; You M; Wu Q; Zhu W; Guo F; Lin W
    Ann Clin Lab Sci; 2022 Nov; 52(6):904-917. PubMed ID: 36564070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.